ADC Therapeutics (ADCT) Accumulated Expenses (2019 - 2026)

ADC Therapeutics has disclosed Accumulated Expenses across 8 years of filings, most recently posting $57.7 million for Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $57.7 million, up 36.72% year-over-year; the trailing twelve-month figure through Mar 2026 was $57.7 million (up 36.72% YoY), and the FY2025 annual result was $58.0 million, down 7.13% from the prior year.
• Accumulated Expenses came in at $57.7 million for Q1 2026 at ADC Therapeutics, down from $58.0 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $68.5 million in Q4 2022 to a low of $42.2 million in Q1 2025.
• The 5-year median for Accumulated Expenses is $53.9 million (2025), against an average of $54.4 million.
• Across the five-year window, Accumulated Expenses retreated 23.93% in 2023 and surged 36.72% in 2026, its largest moves.
• ADC Therapeutics' Accumulated Expenses stood at $68.5 million in 2022, then declined by 23.93% to $52.1 million in 2023, then gained by 19.84% to $62.4 million in 2024, then retreated by 7.13% to $58.0 million in 2025, then decreased by 0.5% to $57.7 million in 2026.
• The last three Accumulated Expenses figures came in at $57.7 million (Q1 2026), $58.0 million (Q4 2025), and $53.9 million (Q3 2025), per Business Quant data.